Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F23%3A00132771" target="_blank" >RIV/00216224:14740/23:00132771 - isvavai.cz</a>
Result on the web
<a href="https://ashpublications.org/blood/article/142/Supplement%201/5759/505860/Exploring-the-Mechanisms-of-Venetoclax-Resistance" target="_blank" >https://ashpublications.org/blood/article/142/Supplement%201/5759/505860/Exploring-the-Mechanisms-of-Venetoclax-Resistance</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
Original language description
Combining Venetoclax, a selective BCL-2 inhibitor, with hypomethylating agents has revolutionized frontline acute myeloid leukemia (AML) treatment. Despite its success, the occurrence of resistance remains a significant concern, limiting the range of available treatment alternatives. Little is known about the mechanism by which the cells escape the treatment. Recent studies have observed MCL1 upregulation in AML cells to promote resistance, and the rationale to use an MCL1 inhibitor became attractive. Although MCL1 inhibitors work exceptionally well in vitro their clinical trials were unsuccessful due to their toxicity. Here, we aim to identify other genes responsible for acquiring resistance and tackle the problem through screening for clinically approved drugs to rapidly benefit the patients with our study.
Czech name
—
Czech description
—

Project
<a href="/en/project/LX22NPO5102" target="_blank" >LX22NPO5102: National institute for cancer research</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)